CN109247483A - 一种供肾透析病人食用的固体饮料及其制备方法 - Google Patents
一种供肾透析病人食用的固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN109247483A CN109247483A CN201710569628.7A CN201710569628A CN109247483A CN 109247483 A CN109247483 A CN 109247483A CN 201710569628 A CN201710569628 A CN 201710569628A CN 109247483 A CN109247483 A CN 109247483A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- solid beverage
- rend dialysis
- dialysis patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 28
- 238000000502 dialysis Methods 0.000 title claims abstract description 28
- 239000007787 solid Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000000843 powder Substances 0.000 claims abstract description 58
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 22
- 239000011707 mineral Substances 0.000 claims abstract description 22
- 229940088594 vitamin Drugs 0.000 claims abstract description 22
- 239000011782 vitamin Substances 0.000 claims abstract description 22
- 239000002131 composite material Substances 0.000 claims abstract description 18
- 241000209140 Triticum Species 0.000 claims abstract description 15
- 235000021307 Triticum Nutrition 0.000 claims abstract description 15
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 13
- 239000004376 Sucralose Substances 0.000 claims abstract description 13
- 239000005862 Whey Substances 0.000 claims abstract description 13
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 13
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 13
- 239000000944 linseed oil Substances 0.000 claims abstract description 13
- 229940035035 polydextrose Drugs 0.000 claims abstract description 13
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 13
- 239000001259 polydextrose Substances 0.000 claims abstract description 13
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 13
- 235000019408 sucralose Nutrition 0.000 claims abstract description 13
- 235000007119 Ananas comosus Nutrition 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 244000099147 Ananas comosus Species 0.000 claims abstract 3
- 235000010755 mineral Nutrition 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960005069 calcium Drugs 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 7
- 229960002104 cyanocobalamin Drugs 0.000 claims description 7
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 7
- 239000011666 cyanocobalamin Substances 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960003966 nicotinamide Drugs 0.000 claims description 7
- 235000005152 nicotinamide Nutrition 0.000 claims description 7
- 239000011570 nicotinamide Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 7
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 7
- 235000005282 vitamin D3 Nutrition 0.000 claims description 7
- 239000011647 vitamin D3 Substances 0.000 claims description 7
- 229940021056 vitamin d3 Drugs 0.000 claims description 7
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 6
- 239000011670 zinc gluconate Substances 0.000 claims description 6
- 229960000306 zinc gluconate Drugs 0.000 claims description 6
- 235000011478 zinc gluconate Nutrition 0.000 claims description 6
- 238000005538 encapsulation Methods 0.000 claims description 5
- 238000012946 outsourcing Methods 0.000 claims description 5
- 229960000342 retinol acetate Drugs 0.000 claims description 5
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 5
- 235000019173 retinyl acetate Nutrition 0.000 claims description 5
- 239000011770 retinyl acetate Substances 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 2
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 244000300264 Spinacia oleracea Species 0.000 claims 1
- 235000009337 Spinacia oleracea Nutrition 0.000 claims 1
- 238000010612 desalination reaction Methods 0.000 claims 1
- -1 malt ketone Chemical class 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 6
- 239000011574 phosphorus Substances 0.000 abstract description 6
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 5
- 239000011591 potassium Substances 0.000 abstract description 5
- 229910052700 potassium Inorganic materials 0.000 abstract description 5
- 239000011734 sodium Substances 0.000 abstract description 5
- 229910052708 sodium Inorganic materials 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 238000005352 clarification Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 241000234671 Ananas Species 0.000 description 9
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 2
- 206010053260 Secondary hyperthyroidism Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种供肾透析病人食用的固体饮料，包括以下重量份的组分：异麦芽酮糖10～30份、麦芽糊精15～20份、海洋鱼骨胶原肽粉10～20份、小麦低聚肽10～15份、脱盐乳清粉10～15份、亚麻籽油粉5～15份、聚葡萄糖5～15份、菠萝果粉3～8份、橘子果粉3～8粉、低聚果糖2～7份、复合维生素 0.3～0.9份、复合矿物质0.3～0.9份、三氯蔗糖0.02‑0.07份。本发明固体饮料中磷、钠、钾含量低，溶解度高，溶解后澄清无沉淀，添加的海洋鱼骨胶原肽粉、小麦低聚肽能够快速补充肾透析病人损失的蛋白质，适合肾透析后的病人食用。
Description
技术领域
本发明涉及营养食品制备领域，具体涉及一种供肾透析病人食用的固体饮料及其制备方法。
背景技术
固体饮料是指用食品原辅料、食品添加剂等加工制成的粉末状、颗粒状或块状供冲调或冲泡饮用的固态制品。固体饮料具有便于携带、易于保存、食用方便、营养丰富、风味独特等特点，备受消费者的青睐。
肾透析疗法是根据半透膜的“膜平衡”原理，使用一定浓度的电解质、葡萄糖组成的透析液与血液中累积的代谢产物、水、电解质进行渗透交换，从而达到治疗的目的。病人在肾透析的过程中体内的蛋白质会丢失，因此，在饮食需要提高蛋白质的摄入，以保证生存的基础能量，避免肌肉蛋白的分解，而高蛋白饮食，会加重患者体内磷的积累，引起继发性甲状腺功能亢进，加重氮质血症相关的毒性症状、代谢性酸中毒以及心血管疾病的发生。肾透析病人存在容量复合超载，应该严格控制水的摄入量，过多的摄入水会导致血压进一步升高，发生心力衰竭、急性肺水肿而危及生命。肾透析后的病人同时存在代谢障碍、电解质紊乱以及酸解平衡失调的问题，其中，高血钾会抑制心脏传导***，导致心率失常，严重时可致患者猝死；高血磷会引起继发性甲状腺功能亢进，促使肾性骨病的发生，影响神经肌肉的兴奋性，导致抽搐；高血钠会加重水、钠潴留，使血压升高，导致心率衰竭及急性肺水肿。因此，肾透析后病人的饮食，在加强蛋白质摄入的同时，应该尽量控制水、磷、钠、钾的摄入。同时，摄入的食物中应含有一定量的脂肪及铁剂，脂肪利于脂溶性维生素的吸收以及提供足够的热量，铁剂有利于贫血的改善。
现有的普通固体饮料，无限制磷、钠、钾的含量，无额外蛋白质补充，不适合肾透析病人食用。
发明内容
本发明所要解决的技术问题是提供一种供肾透析病人食用的固体饮料，它可以解决现有技术中固体饮料磷、钠、钾含量高，无额外蛋白质补充的问题，为此，本发明还要提供一种供肾透析病人食用的固体饮料的制备方法的制备方法。
为了解决上述问题，本发明采用以下技术方案：
本发明的第一方面，提供一种供肾透析病人食用的固体饮料，包括以下重量份的组分：异麦芽酮糖10～30份、麦芽糊精15～20份、海洋鱼骨胶原肽粉10～20份、小麦低聚肽10～15份、脱盐乳清粉10～15份、亚麻籽油粉5～15份、聚葡萄糖5～15份、菠萝果粉3～8份、橘子果粉3～8粉、低聚果糖2～7份、复合维生素0.3～0.9份、复合矿物质0.3～0.9份、三氯蔗糖0.02-0.07份。
优选的技术方案，所述固体饮料包括以下重量份的组分：异麦芽酮糖18份、麦芽糊精14.75份、海洋鱼骨胶原肽粉12份、小麦低聚肽10份、脱盐乳清粉10份、亚麻籽油粉10份、聚葡萄糖9份、菠萝果粉6份、橘子果粉6份、低聚果糖4份、复合维生素0.6份、复合矿物质0.6份、三氯蔗糖0.05份。
优选的技术方案，所述复合维生素包括以下重量份的各组分：抗坏血酸1750～1850份、烟酰胺150～250份、dl-α-醋酸生育酚100～200份、D-泛酸钙60～70份、盐酸吡哆醇16.5～17.5份、核黄素16～17份、盐酸硫胺素15.5～16.5份、醋酸视黄酯13～14份、叶酸3～4份、氰钴胺素0.04～0.05份、胆钙化醇0.015～0.025份。。
优选的技术方案，所述复合矿物质包括以下重量份的各组分：L-乳酸钙40份、葡萄糖酸锌60份。
本发明的第二方面，提供一种上述的供肾透析病人食用的固体饮料的制备方法，包括以下步骤：
步骤一、称取聚葡萄糖5～15份、海洋鱼骨胶原肽粉10～20份、脱盐乳清粉10～15份，混合均匀，加入低聚果糖2～7份，混合均匀，加入异麦芽酮糖10～30份、亚麻籽油粉5～15份及菠萝果粉3～8份，混合均匀后过40目筛，得到物料A；
步骤二、称取麦芽糊精15～20份、小麦低聚肽10～15份、橘子果粉3～8粉，混合均匀，加入复合维生素0.3～0.9份、复合矿物质0.3～0.9份、三氯蔗糖0.02～0.07份，混合均匀，过40目筛，得到物料B；
步骤三、将物料A于物料B混合、封装、内包、外包得到成品。
优选的技术方案，所述复合维生素的制备方法如下：
称取抗坏血酸1750～1850份、烟酰胺150～250份、dl-α-醋酸生育酚100～200份、D-泛酸钙60～70份、盐酸吡哆醇16.5～17.5份、核黄素16～17份、盐酸硫胺素15.5～16.5份、醋酸视黄酯13～14份、叶酸3～4份、氰钴胺素0.04～0.05份、胆钙化醇0.015～0.025份，混合均匀，得到复合维生素。
优选的技术方案，所述复合矿物质的制备方法如下：
称取L-乳酸钙40份、葡萄糖酸锌60份，混合均匀后，得到复合矿物质。
本发明固体饮料中磷、钠、钾含量低，溶解度高，溶解后澄清无沉淀，添加的海洋鱼骨胶原肽粉、小麦低聚肽能够快速补充肾透析病人损失的蛋白质，适合肾透析后的病人食用。
具体实施方式
实施例1
一种供肾透析病人食用的固体饮料，包括异麦芽酮糖180g、麦芽糊精147.5g、海洋鱼骨胶原肽粉120g、小麦低聚肽100g、脱盐乳清粉100g、亚麻籽油粉100g、聚葡萄糖90g、菠萝果粉60g、橘子果粉60g、低聚果糖40g、复合维生素6g、复合矿物质6g 、三氯蔗糖0.5g。
其中，复合维生素包括抗坏血酸17.94g、烟酰胺2.07g、dl-α-醋酸生育酚1571 mgα-TE、D-泛酸钙 650mg、盐酸吡哆醇171mg、核黄素167mg、盐酸硫胺素161mg、醋酸视黄酯134700μgRE、叶酸38600μgDFE、氰钴胺素457ug、胆钙化醇193μg。
复合矿物质包括L-乳酸钙400g、葡萄糖酸锌600g。
固体饮料的制备方法如下：
步骤一、按照上述组分称取聚葡萄糖、海洋鱼骨胶原肽粉、脱盐乳清粉，混合均匀，加入低聚果糖，混合均匀，加入异麦芽酮糖、亚麻籽油粉及菠萝果粉，混合均匀后过40目筛，得到物料A；
步骤二、称取麦芽糊精、小麦低聚肽、橘子果粉，混合均匀，加入复合维生素、复合矿物质、三氯蔗糖，混合均匀，过40目筛，得到物料B；
步骤三、将物料A于物料B混合、封装、内包、外包得到成品。
实施例2
一种供肾透析病人食用的固体饮料，包括异麦芽酮糖100g、麦芽糊精200g、海洋鱼骨胶原肽粉200g、小麦低聚肽120g、脱盐乳清粉130g、亚麻籽油粉50g、聚葡萄糖50g、菠萝果粉30g、橘子果粉80g、低聚果糖70g、复合维生素3g、复合矿物质3g 、三氯蔗糖0.2g。
其中，复合维生素包括抗坏血酸17.5g、烟酰胺2.5g、dl-α-醋酸生育酚1000 mgα-TE、D-泛酸钙700mg、盐酸吡哆醇165mg、核黄素170mg、盐酸硫胺素155mg、醋酸视黄酯140000μgRE、叶酸30000μgDFE、氰钴胺素500ug、胆钙化醇150μg。
复合矿物质包括L-乳酸钙400g、葡萄糖酸锌600g。
固体饮料的制备方法如下：
步骤一、按照上述组分称取聚葡萄糖、海洋鱼骨胶原肽粉、脱盐乳清粉，混合均匀，加入低聚果糖，混合均匀，加入异麦芽酮糖、亚麻籽油粉及菠萝果粉，混合均匀后过40目筛，得到物料A；
步骤二、称取麦芽糊精、小麦低聚肽、橘子果粉，混合均匀，加入复合维生素、复合矿物质、三氯蔗糖，混合均匀，过40目筛，得到物料B；
步骤三、将物料A于物料B混合、封装、内包、外包得到成品。
实施例3
一种供肾透析病人食用的固体饮料，包括异麦芽酮糖180g、麦芽糊精147.5g、海洋鱼骨胶原肽粉120g、小麦低聚肽100g、脱盐乳清粉100g、亚麻籽油粉100g、聚葡萄糖90g、菠萝果粉60g、橘子果粉60g、低聚果糖40g、复合维生素6g、复合矿物质6g 、三氯蔗糖0.5g。
其中，复合维生素包括抗坏血酸18.5g、烟酰胺1.5g、dl-α-醋酸生育酚2000 mgα-TE、D-泛酸钙600mg、盐酸吡哆醇175mg、核黄素160mg、盐酸硫胺素165mg、醋酸视黄酯130000μgRE、叶酸40000μgDFE、氰钴胺素400ug、胆钙化醇250μg。
复合矿物质包括L-乳酸钙400g、葡萄糖酸锌600g。
固体饮料的制备方法如下：
步骤一、按照上述组分称取聚葡萄糖、海洋鱼骨胶原肽粉、脱盐乳清粉，混合均匀，加入低聚果糖，混合均匀，加入异麦芽酮糖、亚麻籽油粉及菠萝果粉，混合均匀后过40目筛，得到物料A；
步骤二、称取麦芽糊精、小麦低聚肽、橘子果粉，混合均匀，加入复合维生素、复合矿物质、三氯蔗糖，混合均匀，过40目筛，得到物料B；
步骤三、将物料A于物料B混合、封装、内包、外包得到成品。
以上应用了具体个例对本发明进行阐述，只是用于帮助理解本发明，并不用以限制本发明。对于本发明所属技术领域的技术人员，依据本发明的思想，还可以做出若干简单推演、变形或替换。
Claims (7)
1.一种供肾透析病人食用的固体饮料，其特征在于，包括以下重量份的组分：异麦芽酮糖10～30份、麦芽糊精15～20份、海洋鱼骨胶原肽粉10～20份、小麦低聚肽10～15份、脱盐乳清粉10～15份、亚麻籽油粉5～15份、聚葡萄糖5～15份、菠萝果粉3～8份、橘子果粉3～8粉、低聚果糖2～7份、复合维生素0.3～0.9份、复合矿物质0.3～0.9份、三氯蔗糖0.02-0.07份。
2.如权利要求1所述的一种供肾透析病人食用的固体饮料，其特征在于，包括以下重量份的组分：异麦芽酮糖18份、麦芽糊精14.75份、海洋鱼骨胶原肽粉12份、小麦低聚肽10份、脱盐乳清粉10份、亚麻籽油粉10份、聚葡萄糖9份、菠萝果粉6份、橘子果粉6份、低聚果糖4份、复合维生素0.6份、复合矿物质0.6份、三氯蔗糖0.05份。
3.如权利要求1所述的一种供肾透析病人食用的固体饮料，其特征在于，所述复合维生素包括以下重量份的各组分：抗坏血酸1750～1850份、烟酰胺150～250份、dl-α-醋酸生育酚100～200份、D-泛酸钙60～70份、盐酸吡哆醇16.5～17.5份、核黄素16～17份、盐酸硫胺素15.5～16.5份、醋酸视黄酯13～14份、叶酸3～4份、氰钴胺素0.04～0.05份、胆钙化醇0.015～0.025份。
4.如权利要求1所述的一种供肾透析病人食用的固体饮料，其特征在于，所述复合矿物质包括以下重量份的各组分：L-乳酸钙40份、葡萄糖酸锌60份。
5.一种供肾透析病人食用的固体饮料的制备方法，其特征在于，包括以下步骤：
步骤一：称取聚葡萄糖5～15份、海洋鱼骨胶原肽粉10～20份、脱盐乳清粉10～15份，混合均匀，加入低聚果糖2～7份，混合均匀，加入异麦芽酮糖10～30份、亚麻籽油粉5～15及菠萝果粉3～8份，混合均匀后过40目筛，得到物料A；
步骤二：称取麦芽糊精15～20份、小麦低聚肽10～15份、橘子果粉3～8粉，混合均匀，加入复合维生素0.3～0.9份、复合矿物质0.3～0.9份、三氯蔗糖0.02～0.07份，混合均匀，过40目筛，得到物料B；
步骤三、将物料A于物料B混合、封装、内包、外包得到成品。
6.如权利要求5所述的一种供肾透析病人食用的固体饮料的制备方法，其特征在于，所述复合维生素的制备方法如下：
称取抗坏血酸1750～1850份、烟酰胺150～250份、dl-α-醋酸生育酚100～200份、D-泛酸钙60～70份、盐酸吡哆醇16.5～17.5份、核黄素16～17份、盐酸硫胺素15.5～16.5份、醋酸视黄酯13～14份、叶酸3～4份、氰钴胺素0.04～0.05份、胆钙化醇0.015～0.025份，混合均匀，得到复合维生素。
7.如权利要求5所述的一种供肾透析病人食用的固体饮料的制备方法，其特征在于，所述复合矿物质的制备方法如下：
称取L-乳酸钙40份、葡萄糖酸锌60份，混合均匀，得到复合矿物质。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710569628.7A CN109247483A (zh) | 2017-07-13 | 2017-07-13 | 一种供肾透析病人食用的固体饮料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710569628.7A CN109247483A (zh) | 2017-07-13 | 2017-07-13 | 一种供肾透析病人食用的固体饮料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109247483A true CN109247483A (zh) | 2019-01-22 |
Family
ID=65051126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710569628.7A Pending CN109247483A (zh) | 2017-07-13 | 2017-07-13 | 一种供肾透析病人食用的固体饮料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109247483A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110731442A (zh) * | 2019-11-28 | 2020-01-31 | 江云 | 一种祛湿消水肿的活性肽固体饮料及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105211884A (zh) * | 2015-08-25 | 2016-01-06 | 广州金酮医疗科技有限公司 | 供糖尿病肾病患者透析后食用的营养组合物及其制备方法 |
| CN106617032A (zh) * | 2016-12-27 | 2017-05-10 | 麦孚营养科技（北京）有限公司 | 一种流质营养食品 |
-
2017
- 2017-07-13 CN CN201710569628.7A patent/CN109247483A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105211884A (zh) * | 2015-08-25 | 2016-01-06 | 广州金酮医疗科技有限公司 | 供糖尿病肾病患者透析后食用的营养组合物及其制备方法 |
| CN106617032A (zh) * | 2016-12-27 | 2017-05-10 | 麦孚营养科技（北京）有限公司 | 一种流质营养食品 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110731442A (zh) * | 2019-11-28 | 2020-01-31 | 江云 | 一种祛湿消水肿的活性肽固体饮料及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9414618B2 (en) | Infant formula milk powder and preparation method thereof | |
| CN103202483A (zh) | 一种补钙营养组合物 | |
| CN1151679A (zh) | 含有绿茶固体、电解质和碳水化合物以提供改善的细胞水合和可饮性的饮料组合物 | |
| CN102550677B (zh) | 一种对中老年人具有保健功能的液态乳制品及其生产方法 | |
| CN106333359A (zh) | 牡蛎多肽螺旋藻营养片及其制备方法 | |
| CN104872614A (zh) | 一种液体食用盐生产工艺 | |
| CN110074397A (zh) | 一种儿童生长发育专用型临床营养配方及其制备方法 | |
| CN103919208A (zh) | 红枣复合饮料及其制备方法 | |
| CN103859041A (zh) | 一种适于婴幼儿补充营养的强化钙粉及其制备方法 | |
| CN109247483A (zh) | 一种供肾透析病人食用的固体饮料及其制备方法 | |
| CN112931857B (zh) | 一种富含高稳定性叶酸和葡萄糖酸亚铁的孕妇营养包与其制备方法 | |
| CN109497368A (zh) | 一种含有刺梨的功能性饮料及其制备方法 | |
| JP4590145B2 (ja) | 低カリウムジュースとその製造方法及びその含有食品 | |
| CN105581331B (zh) | 一种补钙营养组合物 | |
| CN105146666B (zh) | 一种补充b族维生素的固体饮料及其制备方法 | |
| US20200054045A1 (en) | All-Natural Drink Composition for Synthesizing and Regenerating Adenosine Triphosphate (ATP) in Muscle Cells and Neurons, Repairing Exercise-Induced Muscle Fiber Damage, Repletion of Glycogen Stores in the Muscle and Liver, Enhancing Blood Flow to Tissue during Intense Exercise, and Preventing and Reducing Oxidative Damage to Tissues during Exercise with Minimal Gastrointestinal Disturbances | |
| CN104256844A (zh) | 一种缓解疲劳的干混悬剂饮料 | |
| JP7329262B2 (ja) | イリコパウダーとフルクタンパウダーを含有させた栄養補助食品 | |
| CN104982768B (zh) | 一种适合肾病病人能量补充的果冻及其制作方法 | |
| CN106748848A (zh) | 一种制备支链氨基酸的工艺及其应用 | |
| CN109453265A (zh) | 一种聚氰基丙烯酸正丁酯包裹纳米锌绿茶缓释制剂及其应用 | |
| CN105381313A (zh) | 一种维生素d组合物及其用途 | |
| CN104188041A (zh) | 一种人参多维颗粒 | |
| CN115251372B (zh) | 一种适用于非透析肾病患者的食品及其制备方法 | |
| CN102326626A (zh) | 含有玉米、红枣的奶制品及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190122 |
|
| RJ01 | Rejection of invention patent application after publication |